Recent studies have shown the combination of C-reactive protein (CRP) and albumin (The modified Glasgow Prognostic Score, mGPS) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 460 consecutive SCLC patients were screened. Eligible patient was assigned a mGPS of 0, 1, or 2 based on pre-treatment plasma CRP and albumin (0: CRP ≤ 10 mg/L; 1: CRP >10 mg/L and albumin ≥ 35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors for SCLC. A total of 359 patients were analyzed. The mGPS of 0, 1, and 2 was assigned to 66.3, 30.6, and 3.1 % of total patients. For patients with mGPS of 0, 1, and 2, median overall survival (OS) was 30.4, 28.2, and 14.3 months, respectively (P < 0.001). Performance status (P < 0.001), disease stage (P < 0.001) and pre-treatment LDH (P < 0.001) also significantly predicted OS. Multivariate analyses showed mGPS was an independent prognostic factor (P < 0.001). This study demonstrated that higher mGPS independently predicts worse OS for SCLC patients. The assessment of mGPS could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.
Small cell Lung cancer C-reactive protein Albumin Prognosis
This is a preview of subscription content, log in to check access.
This work was supported by: Wu Jieping Medical Foundation Project (Grant No. 08-JC-003), Innovative drug R & D center based on real-time high-throughput cell-based screening platform and large capacity compound library (Grant No. 2013ZX09401003-002), National Natural Science Funds of China (Grant No. 81372502) and National High Technology Research and Development Program of China (Grant No. 2012AA02A502). All the grant supporters have no roles in study design, data collection and analysis, and manuscript preparation.
Ma M, Wang M, Xu Y, Hu K, Liu H, Li L, et al. First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute. Zhongguo Fei Ai Za Zhi. 2014;17(1):8–14. doi:10.3779/j.issn.1009-3419.2014.01.02.PubMedGoogle Scholar
Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523–33.CrossRefPubMedGoogle Scholar
Fizazi K, Cojean I, Pignon JP, Rixe O, Gatineau M, Hadef S, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer. 1998;82(6):1049–55.CrossRefPubMedGoogle Scholar
Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124.CrossRefPubMedGoogle Scholar
Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12. doi:10.1158/1055-9965.EPI-14-0146.CrossRefPubMedGoogle Scholar
Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64. doi:10.1158/1078-0432.CCR-13-1066.CrossRefPubMedGoogle Scholar
Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227–30. doi:10.1038/sj.bjc.6602922.CrossRefPubMedGoogle Scholar
Hwang EC, Hwang IS, Yu HS, Kim SO, Jung SI, Hwang JE, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. Jpn J Clin Oncol. 2012;42(10):955–60. doi:10.1093/jjco/hys124.CrossRefPubMedGoogle Scholar
Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res. 2007;27(4A):1911–5.PubMedGoogle Scholar
Petrovic M, Bukumiric Z, Zdravkovic V, Mitrovic S, Atkinson HD, Jurisic V. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med Oncol. 2014;31(2):823. doi:10.1007/s12032-013-0823-1.CrossRefPubMedGoogle Scholar
Emin Erbaycu A, Gunduz A, Batum O, Zeren Ucar Z, Tuksavul F, Zeki Guclu S. Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol. 2010;46(7):364–9. doi:10.1016/j.arbres.2010.04.005.CrossRefPubMedGoogle Scholar
Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173(1):52–5. doi:10.1097/01.ju.0000146713.50673.e5.CrossRefPubMedGoogle Scholar
Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, Onitsuka T. Postoperative serum C-reactive protein levels in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2010;16(2):85–90.PubMedGoogle Scholar
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–6. doi:10.1038/sj.bjc.6601789.PubMedPubMedCentralGoogle Scholar
McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Color Dis. 2007;22(8):881–6. doi:10.1007/s00384-006-0259-6.CrossRefGoogle Scholar
Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41. doi:10.1016/j.ejca.2011.03.028.CrossRefPubMedGoogle Scholar
Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKee RF, et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 2009;100(5):701–6. doi:10.1038/sj.bjc.6604926.CrossRefPubMedPubMedCentralGoogle Scholar